Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease After Allogeneic Stem Cell Transplantation: A Comparison Among Multiparameter Flow Cytometry, Wilms Tumor 1 Expression and Chimerism Status (Complete vs Low-Level Mixed Chimerism) in Patients with Acute Leukemia

Giovanni Rossi, MD, Angelo Michele Carella, MD, Maria Marta Minervini, Lucia Savino, Andrea Fontana, MSc, Fabio Pellegrini, MSc, Michele Mario Greco, MD, Emanuela Merla, MD, Giovanni Quarta, MD, Giacomo Loseto, MD, Silvana Capalbo, MD, Gaetano Palumbo, MD, Nicola Cascavilla

Blood (2012) 120 (21): 1971.

https://doi.org/10.1182/blood.V120.21.1971.1971

Published: 2012

Journal Articles

Relapsed or Refractory Multiple Myeloma: Prospective Study with Bortezomib, Non-Pegylated Liposomal Doxorubicin and Dexamethason (PAD Regimen)

Antonietta Pia Falcone, MD, Grazia Sanpaolo, MD, Giovanni Rossi, MD, Carlo Bodenizza, MD, Angelo Michele Carella, MD, Matteo Dell' Olio, MD, Michele Mario Greco, MD, Antonio La Sala, MD, Saverio Mantuano, MD, Lorella Melillo, MD, Emanuela Merla, MD, Michele Nobile, MD, Potito R Scalzulli, M.D., Silvana Capalbo, MD, Nicola Cascavilla, MD

Blood (2012) 120 (21): 5032.

https://doi.org/10.1182/blood.V120.21.5032.5032

Published: 2012

Journal Articles

Intermediate Dose Melphalan, Bortezomib, Thalidomide, Dexametasone (MVTD) Conditioning Therapy and ASCT in Relapsed Multiple Myeloma Patients: A Single Center Experience.

Potito Rosario Scalzulli, MD, Maria Rosa Valvano, SD, Carlo C. Bodenizza, MD, Angelo Michele Carella, MD, Matteo M. Dell’Olio, MD, Antonietta A.P. Falcone, MD, Michele Mario Greco, MD, Antonio A. La Sala, MD, Francesco F.S. Mantuano, MD, Lorella L. Melillo, MD, Emanuela E. Merla, MD, Michele M. Nobile, MD, Sanpaolo G. Sanpaolo, MD, Nicola N. Cascavilla, MD

Blood (2007) 110 (11): 5117.

https://doi.org/10.1182/blood.V110.11.5117.5117

Published: 2007

Journal Articles

Gemtuzumab Ozogamicin as Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Patients with Acute Myeloid Leukemia (AML).

Nicola Cascavilla, MD, Carlo Bodenizza, MD, Angelo Michele Carella, MD, Matteo Dell’Olio, MD, Antonietta Pia Falcone, MD, Michele Mario Greco, MD, Antonio La Sala, MD, Saverio Mantuano, MD, Lorella Melillo, MD, Emanuela Merla, MD, Michele Nobile, MD, Grazia Sanpaolo, MD, Potito Scalzulli, MD

Blood (2007) 110 (11): 4380.

https://doi.org/10.1182/blood.V110.11.4380.4380

Published: 2007

Journal Articles

Use of Intrathecal Liposomal Cytarabine (DepoCyte) as Treatment of Lymphomatous Meningitis.

Nicola Cascavilla, MD, Carlo Bodenizza, MD, Angelo Michele Carella, MD, Matteo Dell’Olio, MD, Antonietta Falcone, MD, Michele Mario Greco, MD, Antonio La Sala, MD, Saverio Mantuano, MD, Lorella Melillo, MD, Emanuela Merla, MD, Michele Nobile, MD, Grazia Sanpaolo, MD, Potito Scalzulli, MD

Blood (2006) 108 (11): 4677.

https://doi.org/10.1182/blood.V108.11.4677.4677

Published: 2006

NARROW

Minimal Residual Disease After Allogeneic Stem Cell Transplantation: A Comparison Among Multiparameter Flow Cytometry, Wilms Tumor 1 Expression and Chimerism Status (Complete vs Low-Level Mixed Chimerism) in Patients with Acute Leukemia

Relapsed or Refractory Multiple Myeloma: Prospective Study with Bortezomib, Non-Pegylated Liposomal Doxorubicin and Dexamethason (PAD Regimen)

Intermediate Dose Melphalan, Bortezomib, Thalidomide, Dexametasone (MVTD) Conditioning Therapy and ASCT in Relapsed Multiple Myeloma Patients: A Single Center Experience.

Gemtuzumab Ozogamicin as Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Patients with Acute Myeloid Leukemia (AML).

Use of Intrathecal Liposomal Cytarabine (DepoCyte) as Treatment of Lymphomatous Meningitis.

Email alerts

ASH Publications

American Society of Hematology

Minimal Residual Disease After Allogeneic Stem Cell Transplantation: A Comparison Among Multiparameter Flow Cytometry, Wilms Tumor 1 Expression and Chimerism Status (Complete vs Low-Level Mixed Chimerism) in Patients with Acute Leukemia

Relapsed or Refractory Multiple Myeloma: Prospective Study with Bortezomib, Non-Pegylated Liposomal Doxorubicin and Dexamethason (PAD Regimen)

Intermediate Dose Melphalan, Bortezomib, Thalidomide, Dexametasone (MVTD) Conditioning Therapy and ASCT in Relapsed Multiple Myeloma Patients: A Single Center Experience.

Gemtuzumab Ozogamicin as Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Patients with Acute Myeloid Leukemia (AML).

Use of Intrathecal Liposomal Cytarabine (DepoCyte) as Treatment of Lymphomatous Meningitis.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only